Cima deal

Sterling Winthrop Inc. elected not to exercise its option to commercialize in the U.S. and Canada five of the 15 OraSolv analgesic and cough/cold/flu, allergy and sinus products that are part of the companies’ option and development agreement. Sterling retained its option to commercialize the products internationally, and retains the option to enter into license agreements to market the other 10 products covered by the agreement.

CIMA plans to seek other partners to commercialize the five products in the U.S. and Canada. ...